PerkinElmer, Inc. (NYSE:PKI) has earned a consensus rating of “Hold” from the seventeen analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and five have given a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $78.38.
Several equities analysts recently commented on the stock. Zacks Investment Research upgraded shares of PerkinElmer from a “hold” rating to a “buy” rating and set a $85.00 price target on the stock in a report on Thursday. ValuEngine upgraded shares of PerkinElmer from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Robert W. Baird restated a “buy” rating and issued a $88.00 target price on shares of PerkinElmer in a research note on Friday, January 26th. Barclays upped their target price on shares of PerkinElmer from $69.00 to $73.00 and gave the stock an “underweight” rating in a research note on Friday, January 26th. Finally, Bank of America dropped their target price on shares of PerkinElmer from $86.00 to $83.00 and set a “hold” rating on the stock in a research note on Tuesday, May 1st.
PerkinElmer traded up $0.01, hitting $76.03, during mid-day trading on Monday, MarketBeat reports. 10,367 shares of the stock traded hands, compared to its average volume of 627,965. The company has a market capitalization of $8.43 billion, a price-to-earnings ratio of 26.27, a PEG ratio of 1.75 and a beta of 0.84. PerkinElmer has a 52 week low of $61.89 and a 52 week high of $84.49. The company has a current ratio of 1.33, a quick ratio of 0.93 and a debt-to-equity ratio of 0.73.
PerkinElmer (NYSE:PKI) last issued its quarterly earnings results on Monday, April 30th. The medical research company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.61 by $0.02. The company had revenue of $644.00 million for the quarter, compared to the consensus estimate of $618.97 million. PerkinElmer had a net margin of 11.73% and a return on equity of 13.26%. The firm’s revenue was up 0 compared to the same quarter last year. During the same period in the prior year, the firm posted $0.55 EPS. equities analysts forecast that PerkinElmer will post 3.61 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, August 10th. Stockholders of record on Friday, July 20th will be given a $0.07 dividend. The ex-dividend date is Thursday, July 19th. This represents a $0.28 annualized dividend and a dividend yield of 0.37%. PerkinElmer’s payout ratio is presently 9.66%.
In related news, insider Daniel R. Tereau sold 1,156 shares of the stock in a transaction that occurred on Wednesday, April 18th. The shares were sold at an average price of $77.00, for a total transaction of $89,012.00. Following the completion of the sale, the insider now owns 6,784 shares of the company’s stock, valued at $522,368. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Frank Anders Wilson sold 103,656 shares of the stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $73.94, for a total transaction of $7,664,324.64. Following the sale, the insider now directly owns 93,624 shares of the company’s stock, valued at approximately $6,922,558.56. The disclosure for this sale can be found here. 2.10% of the stock is currently owned by corporate insiders.
A number of large investors have recently bought and sold shares of PKI. Bank of Montreal Can lifted its position in PerkinElmer by 31.0% during the fourth quarter. Bank of Montreal Can now owns 52,240 shares of the medical research company’s stock valued at $3,820,000 after acquiring an additional 12,372 shares during the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of PerkinElmer by 3.3% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 648,194 shares of the medical research company’s stock worth $47,396,000 after buying an additional 20,823 shares during the last quarter. Oakbrook Investments LLC purchased a new position in shares of PerkinElmer in the fourth quarter worth $301,000. State of Alaska Department of Revenue raised its holdings in shares of PerkinElmer by 111.8% in the fourth quarter. State of Alaska Department of Revenue now owns 18,850 shares of the medical research company’s stock worth $1,376,000 after buying an additional 9,950 shares during the last quarter. Finally, Smith Graham & Co. Investment Advisors LP raised its holdings in shares of PerkinElmer by 21.7% in the fourth quarter. Smith Graham & Co. Investment Advisors LP now owns 67,880 shares of the medical research company’s stock worth $4,963,000 after buying an additional 12,090 shares during the last quarter. 93.71% of the stock is owned by institutional investors.
PerkinElmer Company Profile
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment develops and offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil.
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.